Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Safety, pharmacokinetics, pharmacodynamics [CD11b/CD18 (Mac-1) expression] and efficacy.

Phase 1

Boehringer Ingelheim